GlassScriptPhysician profile
Marie T Tarleton
NPI 1659493617
$2,373.30
in general payments reported to CMS, 2019-2025
23 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $474 · 2023: $547 · 2024: $441 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.98 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.37 | 2021-2025 | |
| Abbott Laboratories | $277.72 | 2021-2023 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $169.13 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $115.86 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $104.52 | 2022 | |
| Mannkind Corporation | $100.49 | 2022 | |
| Boston Scientific Corporation | $98.17 | 2023 | Wavewriter Alpha Prime 16 |
| Grt US Holding, INC. | $97.59 | 2022 | |
| Exact Sciences Corporation | $95.31 | 2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $81.33 | 2025 | |
| Novo Nordisk INC | $80.69 | 2021 | |
| Gilead Sciences, INC. | $77.02 | 2021 | |
| Pfizer INC. | $75.60 | 2025 | |
| Tactile Systems Technology INC | $71.88 | 2023 | Flexitouch Plus, Entre Plus |
| Shield Therapeutics INC | $69.92 | 2023 | Accrufer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $68.73 | 2023 | Valtoco |
| Sanofi-Aventis U.S. LLC | $67.54 | 2024 | |
| Tris Pharma INC | $63.00 | 2024 | Quillichew Er, Quillivant, Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $62.35 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $52.41 | 2025 | Uptravi, Opsumit |
| Cequr Corporation | $51.70 | 2025 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $20.22 | 2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Tarleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.